Fimasartan;Indapamide
- Generic Name
- Fimasartan;Indapamide
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fasting Conditions
Phase 1
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06744426
- Locations
- π°π·
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions
Phase 1
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 58
- Registration Number
- NCT06744127
- Locations
- π°π·
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-1 and BR1015-2 in Healthy Volunteers Fed Conditions
Phase 1
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT06744062
- Locations
- π°π·
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015 and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions
Phase 1
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 49
- Registration Number
- NCT06744439
- Locations
- π°π·
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fasting Conditions in Healthy Volunteers
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 57
- Registration Number
- NCT06008028
- Locations
- π°π·
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 44
- Registration Number
- NCT06008015
- Locations
- π°π·
Clinical Research Center, H PLUS Yangji Hospital, Seoul, Gwanakgu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath